摘要:
The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.
摘要:
The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21, R22, R23 and R24 are as defined in the description and claims.
摘要:
The present invention provides novel methods for preparing a key intermediate, 3,5-di-O-acyl-2-fluoro-2-C-methyl-D-ribono-γ-lactone (2), for the preparation of 1-(2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranosyl)cytosine (1), which is a potent and selective anti-hepatitis C virus agent.
摘要:
The invention is concerned with new phosphine ligands of the formula I whereinR1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3−, —CO—NR8R8′, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl;R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4′ and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4′ and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8′; and R8 and R8′ are independently of each other hydrogen, alkyl or aryl;metal complexes with such ligands as well as the use of such metal complexes as catalysts in asymmetric reactions.
摘要:
The present invention relates to compounds of the formula I: wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
摘要:
The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3−, —CO—NR8R8′, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4′ and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4′ and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8′; and R8 and R8′ are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of such metal complexes as catalysts in asymmetric reactions.
摘要翻译:本发明涉及式I的新膦配体,其中R 1和R 2彼此独立地为烷基,芳基,环烷基或杂芳基,所述烷基,芳基, 环烷基或杂芳基可以被烷基,烷氧基,卤素,羟基,氨基,一或二烷基氨基,芳基,-SO 2 -R 7,-SO 3, 羧基,烷氧基羰基,三烷基甲硅烷基,二芳基烷基甲硅烷基,二烷基芳基甲硅烷基或三芳基甲硅烷基;取代或未取代的苯基, R 3是烷基,环烷基,芳基或杂芳基; R 4'和R 4'彼此独立地表示氢,烷基或任选取代的芳基; 或R 4'和R 4与它们连接的C原子一起形成3-8元碳环; 虚线不存在或存在并形成双键; R 5和R 6彼此独立地为氢,烷基或芳基; 或连接在一起形成3-8元碳环或芳环; R 7是烷基,芳基或NR 8 R 8; R 8和R 8'彼此独立地为氢,烷基或芳基; 与这种配体的金属络合物以及在不对称反应中使用这样的金属络合物作为催化剂。
摘要:
The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21, R22, R23 and R24 are as defined in the description and claims.
摘要:
The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.
摘要:
The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3−, —CO—NR8R8′, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4′ and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4′ and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8′; and R8 and R8′ are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of such metal complexes as catalysts in asymmetric reactions.
摘要:
The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.
摘要翻译:本发明涉及用于制备下式的2-氨基 - [5-(1-羟基-2-羟基或卤代 - 乙基)] - 吡嗪衍生物的生物催化不对称还原:其中R是低级烷基羰基或氨基保护基, R 1是羟基或卤素。 这些化合物是制造葡糖激酶活化剂的关键中间体。